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O R I G I N A L  R E S E A R C H
Patients’ Preferences Regarding Osteoarthritis 
Medications: An Adaptive Choice-Based Conjoint 
Analysis Study
This article was published in the following Dove Press journal: 
Patient Preference and Adherence
Basem Al-Omari 1 
Peter McMeekin2
1College of Medicine & Health Sciences, 
Khalifa University, Abu Dhabi, United 
Arab Emirates; 2School of Health & Life 
Sciences, University of Northumbria, 
Newcastle-Upon-Tyne, UK 
Background and Objective: Osteoarthritis (OA) patients consider ranges of harms and 
benefits offered by alternative pharmaceutical treatments. Choice-based experiments provide 
a mechanism to value outcomes, but they can pose a significant burden on respondents. Thus, 
the number of attributes studied is typically artificially restricted. We used an adaptive 
choice-based conjoint (ACBC) method that allows the inclusion of more attributes affecting 
patients’ preferences regarding non-invasive pharmaceutical treatment for OA than tradi-
tional choice-based technique to better understand the trade-offs that OA patients consider, 
without increasing respondents’ burden.
Methods: After consulting with OA patients and public involvement (PPI) group, we con-
structed an online ACBC survey consisting of 9 attributes and a total of 31 levels (two benefits, 
four harms and three concerning the availability and modality of treatment). A cohort of patients 
with a diagnosis of OA and reporting joint pain within the last 12 months were recruited.
Results: Our study (n 43) showed that the most important factor in choosing OA medication 
was the risk of heart attacks and strokes (19.5%), followed by the risk of addiction (18.4%), 
risk of kidney and liver side effects (17.5%), risk stomach side effects (14.6%), availability 
(11.6%), frequency of use (5.3%), pain reduction (5%), way of taking medication (4.6%) and 
mobility improvement (3.5%).
Conclusion: ACBC provides a mechanism for understanding patient preferences that 
address the limitations of traditional choice-based experiments. For OA patients, avoidance 
of the risk of side effects were the most affecting medication choices, and reductions in pain 
and mobility were the least. Clinicians discussing options for medication with OA patients 
should discuss the potential trade-offs in terms of risks and benefits.
Keywords: osteoarthritis, adaptive choice-based conjoint, conjoint analysis, patient 
preferences
Plain Language Summary
This study is using the novel online adaptive choice-based conjoint (ACBC) technique to 
collect and quantify patient preferences for osteoarthritis treatment. It addresses the limita-
tions that were reported in previous similar studies by allowing researchers to include a large 
number of medication characteristics without complicating the conjoint task. It is an exten-
sion of previously published feasibility and pilot studies and it includes 9 attributes and 
a total of 31 levels, which makes it the most comprehensive choice experiment study 
regarding pharmaceutical treatment for osteoarthritis.
The study is potentially underpowered (n = 43) and the generalisability to osteoarthritis 
population might be limited in terms of treatment preferences. However, there is no 
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consensus in relation to the sample size for conjoint studies and 
the novelty and contribution that the ACBC method introduces 
such as including a large number of attributes and levels com-
pensates for this limitation. An ACBC questionnaire generally 
takes a longer time to complete than the traditional choice-based 
experiments but captures more information from each 
participant.
The results of this study indicate that patients’ preferences for 
pharmaceutical treatment for osteoarthritis is predominantly dri-
ven by patients desire to avoid the risk of side effects. This study 
also introduces ACBC as a practical tool that can be used to elicit 
patients’ preferences for the pharmaceutical treatment of OA.
Background
Pharmaceutical treatments for osteoarthritis (OA) are pre-
ference-sensitive.1,2 Studies have consistently shown that 
patients consider a range of implications of different 
treatments.3,4 More specifically, patients explicitly con-
sider the trade-offs between different attributes of alterna-
tives, in terms of benefits and harms.5–7 To date, the 
benefit of pain reduction and the harms from adverse 
events have been most often identified as the most impor-
tant attributes to OA patients.1,3,8 However, some studies 
found that other benefits including improvement in func-
tion or reduction in pain were the most important.9,10 
Other studies found that patients were more concerned 
about the risk of side effects.11–13 Costs and mode of 
administration have also been shown to be predictors of 
preferences in some studies.14–17 Therefore, eliciting 
patients´ preferences for OA treatment may enable thera-
pists to better develop and implement patient-oriented 
treatment.18
The methods used to elicit patient preferences are 
referred to as stated-preference methods.19,20 The use of 
these methods in estimating the value of different attri-
butes of health care is increasing.21,22 Stated-preference 
methods such as conjoint analysis require participants to 
make explicit choices between scenarios described in 
terms of levels of attributes.23 Where the level of an 
attribute refers to the amount or degree of that attribute, 
for example, an attribute could be “pain level” and levels 
of that attribute could be “no pain, mild pain, moderate 
pain, and severe pain”. Conjoint analysis is one of the 
survey methodologies that can be used to study prefer-
ences and quantify the trade-off that patients make 
between the different treatment factors on decision- 
making.24,25 Unlike traditional questionnaires, conjoint 
analysis poses several hypothetical scenarios and ask 
patients to rate/rank (rating/ranking approach) them or 
choose their preferred scenario (choice-based approach). 
If appropriately designed, implemented, analysed and 
interpreted, choice-based experiments offer practical alter-
natives and complement to the existing methods of valua-
tion and preference elicitation by providing rich data 
sources for decision-making, allowing investigation of 
many types of questions, some of which otherwise would 
be intractable analytically.26
Choice-based experiments require an attribute-based 
measure of benefits.27 The value of healthcare is the sum 
of the values of each attribute.22 By modifying the levels 
and making choices between sets of attributes at differing 
levels, the additional amount of one attribute required to 
compensate for a reduction in others can be estimated and 
a set of values determined for all attribute levels. This 
means that choice-based designs assume that something 
can be valued in terms of the sum of the values of the set 
of attributes that define that thing, rather than the thing 
per se.26 It is consistent with consumer choice theory 
because it assumes the observed choices made reveal the 
true preferences of the participant. However, as the num-
ber of attributes and their associated levels increase, the 
complexity of choices increases along with the number of 
choices that need to be made in order to estimate these 
values.28 A full factorial design is usually used to generate 
all possible combinations of all levels of the included 
attributes.29 An omission of an attribute from a choice- 
based experiment means that the preferences of the parti-
cipant would not be completely nor accurately captured.26
Techniques, where patients are given overlapping sub-
sets of choices and responses combined, can address the 
issue of respondent burden.29 However, this is at the cost 
of increasing the number of patients needed to complete 
the questionnaire. Generally, the higher number of attri-
butes in a traditional choice study requires a larger 
sample.30 For example, Laba and colleagues required 
a sample of 503 participants for a study that included 7 
attributes and 20 levels,11 while Ratcliffe and colleagues 
recruited 412 participants to study 5 attributes and 15 
levels.12 Alternatively, the number of attributes and their 
levels can also be restricted, such as Fraenkel and collea-
gues study,9 that included 4 attributes and 12 levels in 
a sample of 304 participants and Byun and colleagues,10 
who recruited 100 participants to quantify the values of 4 
attributes and 12 levels. Therefore, the choice of the 
design for a choice experiment is critical as it determines 
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which attributes’ effects and their interactions are 
identifiable.31
In this paper, we estimate patients’ preferences for OA 
treatments using a novel adaptive choice-based conjoint 
(ACBC) technique. ACBC analysis is a technique that uses 
choice data and incorporates it into an adaptive interviewing 
experience,32 and it accommodates a greater number of 
attributes and levels than previous conjoint-analysis 
methods.33 Previous conjoint studies were unable to include 
all medication characteristics such as kidney and liver side 
effects, as that would have overly complicated the question-
naire and suggested that the inclusion of these additional 
adverse effects. Even if by doing so, it may improve our 
understanding of patient preference regarding OA 
treatment.14–16,34 The use of ACBC addresses this reported 
limitation. The advantages of ACBC that it provides more 
information about patient preferences.35 ACBC is imple-
mented in software and seeks to reduce the number of 
choices a patient is presented with by eliminating irrelevant 
choices from the choice sets presented to a patient, the 
patient is required to complete shorter choice sets compared 
to non-adaptive technique.33,35 This means that it is not 
easily possible to compare sample sizes between ACBC 
studies and other traditional conjoint methods where one 
responded may only contribute data about a small number 
of characteristics. Furthermore, due to the format of ACBC 
studies, respondents may be more engaged in the survey- 
taking experience and provide answers that are more in-line 
with their actual choice behaviour.32
Taking into consideration the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 
guidelines for conjoint-analysis to pilot conjoint 
studies,36 we conducted a pilot test of the ACBC ques-
tionnaire with a research user group (RUG) to gather 
patient feedback.8 In another study, we have previously 
established that ACBC is a feasible method for eliciting 
patients’ preferences regarding OA treatment.37 The pilot 
study considered the patients’ preferences for OA treat-
ment by collecting date from 11 OA patients who were 
members of patients and public involvement (PPI) group.8 
Furthermore, we have also used this method to generate an 
individual patient’s preferences.28
Methods
Patient and Public Involvement
The research design, attributes and levels, questionnaire 
development, and presentation of data were developed and 
tailored based on the feedback provided by the research 
users’ group (RUG) members, part of the wider public and 
patient involvement (PPI) group in the Arthritis Research 
UK Primary Care Centre at Keele University, UK. This 
study is an extension of a pilot study,8 two feasibility 
studies,37 and individual patient preference analysis 
study.28 Due to geographical distance the initial RUG 
members were not directly involved in the recruitment of 
participants. However, their recommendation regarding the 
inclusion criteria was considered and applied. The pre-
vious feasibility studies were comprehensive and had 
established 1). the clarity of the ACBC question for-
mats; 2). the amount of information that participants 
needed to understand the ACBC task; 3). participants 
acceptance of the design and wording of the ACBC 
task; 4). the practicality of completing the ACBC task; 
and 5). whether the stated preference from the ACBC task 
reflected the participants’ beliefs of their preferences.37
Participants and Recruitment
Patients were from Newcastle-upon-Tyne and surrounding 
areas in the north-east of England. Posters, emails, and 
newsletters about the study were published via 
Healthwatch Newcastle, Healthwatch North-East, and 
staff and students at the faculty of health and life sciences 
at Northumbria University. Healthwatch Newcastle is 1 of 
the 152 Healthwatch that work in each local authority area 
in England,38 and they have statutory powers under the 
Health and Social Care Act 2012.39 Healthwatch aims to 
help children, young people and adults to have a say about 
health services and to include people who sometimes 
struggle to be heard and are independent of health-care 
providers.38 For this ACBC study, the aim was to recruit 
a total of 40 for analysis of patients’ preferences regarding 
the non-invasive pharmaceutical treatment of OA. This 
number of participants was determined after consultation 
with the Healthwatch team and based on the available 
resources and anticipated rates of recruitment.
Patients were included in the study if they 1). are adults 
above the age of 18 years old, 2). have a diagnosis of OA 
from their doctor, 3). reporting joint pain in the past 12 
months. Patients were excluded if they 1). are not com-
plaining of joint pain, 2). have other illnesses that may 
contribute to or cause their joint pain such as rheumatoid 
arthritis or osteoporosis. Patients who were interested in 
taking part in the study contacted either the Healthwatch 
team or the researcher directly. This method of recruitment 
provided patients with the choice to participate or not, as 
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the researcher and Healthwatch team had no patient–pro-
vider relationship that may impact actual healthcare based 
on the patients’ decision to participate.
Attributes and Levels
Defining attributes and levels is one of the most critical 
aspects of designing a good conjoint analysis study.40 The 
attributes and levels were identified based on being factors 
that influence patient preference regarding the non- 
invasive pharmaceutical treatment of OA. The inclusion 
of the attributes and levels were based upon 1). a full 
systematic search to identify the attributes used in similar 
studies, 2). recommendation to include more side effect 
attributes by experts in the field,34 3). an ACBC feasibility 
study,37 4). discussion with a rheumatologist, rheumatol-
ogy pharmacist, research methodologists, PPI coordina-
tors, and RUG members. For example, patients at the 
RUG were given the choice of having evidence-based 
percentage levels representing the actual risk of medica-
tion or other wording and they opted to “No, Low, 
Moderate, and High” as levels for the risk of adverse 
effects. The RUG patients felt that the actual percentage 
of risks such as “2%, 4%, and 8%” for a medication 
adverse effect would not mean much to them and they 
will not be able to understand it in terms of trading-off 
levels against each other. The RUG suggested using per-
centage for the benefit attributes to make it easier for them 
to differentiate between a benefit and adverse event attri-
bute. Furthermore, the RUG suggested eliminating 0% and 
100% as they must expect some benefit but this will never 
be 100% from the medications. Similar free choices were 
given to the patients in all attributes and levels and the 
wording was developed based on their suggestions. The 
financial cost was not included in this study because the 
cost of medications for older persons in the UK healthcare 
system is rarely a direct issue. In this study, we formulated 
attributes and levels that are realistic within the context of 
the study and are credible to respondents.35,40
In this study, the ACBC value-set had a total of 9 
attributes and 31 levels compared to a total of 8 attributes 
and 28 levels in the pilot (Table 1). To address the limita-
tion identified during the pilot,8 (imbalance between risks 
and benefits attributes 4 to 1), an additional benefit attri-
bute was added. While OA treatments aim to reduce pain 
and improve mobility.41,42 The previously used benefit 
attribute in the pilot,8 and feasibility,37 studies (Expected 
percentage of benefit) was split into two attributes in this 
study (How much you would expect mobility 
improvement AND How much you would expect pain 
reduction), representing pain reduction and mobility 
improvement. These two attributes were originally devel-
oped with the assistant of the RUG and experts in the field, 
and the decision to combine them was a result of a need to 
reduce the number of attributes. The wording used in all 
attributes and levels were based on RUG recommenda-
tions and suggestions in the pilot and feasibility studies.8,37
ACBC Questionnaire and Data 
Collection
Patients who expressed an interest in taking part in this 
study were contacted by phone and/or email to determine 
their eligibility to be included. Eligible participants were 
given the option of completing the ACBC questionnaire 
online independently or being visited at home to complete 
the ACBC questionnaire online. All patients were given 
a Uniform Resource Locator (URL), their unique user-
name, and the password. A Prompt email was sent after 
two weeks and three weeks to remind participants who did 
not complete the ACBC questionnaire. All questionnaires 
were completed between January/June 2017.
The web-based interactive ACBC questionnaire was 
developed by the lead researcher BA using the SSI web 
version (8.2.4). The process of developing the ACBC 
questionnaire was the same as that used previously by Al- 
Omari and colleagues,8,28,37 and was consistent with the 
PPI recommendations in these studies. The first screen in 
the ACBC questionnaire introduced the task and included 
the consent form. This was followed by questions on 
demography and the respondents’ health. The main 
ACBC task consisted of three stages:
Stage 1: Build your own (BYO) section, which intro-
duces all attributes and levels and asks the respondents to 
indicate the preferred level for each attribute (see Figure 1 
for an example of this question).
Stage 2: Screening section, which includes three dif-
ferent types of questions: 2.1). Screening questions, these 
are scenarios questions generated by the software based on 
each respondent’s preferred levels in the first stage (see 
Figure 2 for an example of this question). 2.2). 
Unacceptable questions, these are questions where respon-
dents indicate if they are trying to avoid a specific level 
(see Figure 2 for an example of this question). 2.3). Must- 
Have questions, these are questions where respondents 
indicate the most important level that they are not willing 
trade-off (see Figure 2 for an example of this question).
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Stage 3: Choice tasks section, which includes a series 
of choice tasks presenting three scenarios in each screen 
and asks the participants to choose their preferred scenario 
(see Figure 3 for an example of this question).
Our study addressed the key recommended points 
before fielding an ACBC study, as recommended by 
Sawtooth (the developer of the ACBC software) 
(Table 2).43
Data Analysis
Descriptive statistics were used to summarise frequencies 
with percentages for categorical variables. The ACBC 
software has a built-in Hierarchical Bayes (HB) analysis 
model which was used to analyse the relative importance 
and part-worth of the attributes and levels. HB model 
requires less information per subject than other statistical 
models for choice analysis.44 The attributes are measured 
by the relative importance, which represents the weight 
that patients place on each attribute in comparison to the 
remaining attributes.28 The levels of the attributes are 
measured by part-worth (utilities), which represent the 
weight that patients place on each level in comparison to 
the remaining levels of the same attribute.33
An attribute relative importance is estimated “by con-
sidering how much difference each attribute could make in 
the total utility of a product. That difference is the range in 
the attribute’s utility values”.45 The relative importance is 
ratio-scaled and relative. The combined relative impor-
tance for all attributes sums up to 100%. An attribute 
with the relative importance of 20% is twice as important 
as an attribute with the relative importance of 10% within 
the same set of attributes used in the study.45 For example, 
if a study included attributes A, B, C, and D and the 
Table 1 Attributes and Levels Used the Pilot and in This ACBC 
Study
Attribute Levels




Availability 1. Prescription drug
2. Over-the-counter drug
3. Internet purchase drug
Way of taking the medication 1. Cream/Gel
2. Oral
Frequency 1. Once a day
2. Twice a day



















1. Expect 25% 
mobility 
improvement
2. Expect 50% 
mobility 
improvement
3. Expect 75% 
mobility 
improvement
How much you 
would expect 
pain reduction
1. Expect 25% 
pain 
reduction
2. Expect 50% 
pain 
reduction
3. Expect 75% 
pain 
reduction
Risk of gastric ulcer 1. No risk of gastric ulcer
2. Low risk of gastric ulcer
3. Moderate risk of gastric 
ulcer
4. High risk of gastric ulcer
Risk of addiction 1. No risk of addiction
2. Low risk of addiction
3. Moderate risk of addiction
4. High risk of addiction
Risk of kidney and liver impairment 1. No risk of kidney and liver 
impairment
2. Low risk of kidney and 
liver impairment
3. Moderate risk of kidney 
and liver impairment
4. High risk of kidney and 
liver impairment
(Continued)
Table 1 (Continued). 
Attribute Levels




Risk of heart attacks and strokes 1. No risk of heart attacks 
and strokes
2. Low risk of heart attacks 
and strokes
3. Moderate risk of heart 
attacks and strokes
4. High risk of heart attacks 
and strokes
Patient Preference and Adherence 2020:14                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2505




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Figure 1 An example of Build Your Own (BYO) question.
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Figure 2 Examples of the screening section questions.
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relative importance of these attributes were 20%, 30%, 
10%, and 40%, respectively, this would mean that the 
most important attribute is “D” and the least important is 
“C”. It also means that attribute “D” is twice as important 
as attribute “A” and four times as important as attri-
bute “C”.
The ACBC HB analysis estimates individual-level 
utility coefficients and rescales all levels in each attribute 
using zero-centred differences method.28 This analysis 
allows the estimation of individual utility coefficients 
to be constrained based on each participant’s response 
to additional questions, or globally when all respondents 
are assumed to have the same preference order.46 The 
utility for each level is a number that represents the 
weight that a respondent puts on that particular level in 
the context of other levels within the same attribute.28 
The level that holds the highest utility value in each 
attribute is the most preferred one. The level that holds 
the lowest utility value (in the minus) is that the patient 
least prefers and does not represent negative utilities or 
disutility. Utilities of all levels in each attribute are 
scaled to sum to zero.47 Unlike traditional conjoint- 
analysis, ACBC utility scores are arbitrary given by the 
software and they present interval data scaled to an 
arbitrary additive constant within each attribute.45 
Therefore, the utility value of one level in an attribute 
cannot be arithmetically compared with the value of 
another level in another attribute. The utility values and 
the intervals between the values have a meaning within 




Forty-three participants in total were recruited and com-
pleted the online ACBC questionnaire (response rate (RR) 
100% - 43 recruited and the same 43 completed the study). 
All participants were adults (13 males [30.2%] and 30 
females [69.8%]), who reported joint pain within the last 
12 months and have a diagnosis of OA confirmed by their 
doctors in at least one joint. The mode age categories were 
Figure 3 An example of the choice task question.
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40–49 and 70–79 years old. Only one participant was 
under the age of 30 years old. (Table 3).
The majority of participants (65.1%) had OA for over 5 
years. About 93% of the participants reported that joint 
pain affected their normal life, 72.1% reported that effect 
to be moderate to extreme, and 7% reported that joint pain 
does not interfere with their normal life at all (Table 3).
The majority of patients (39 patients - 90.7%), reported 
using or have used paracetamol for the treatment of OA, 
while only two participants (4.7%) reported using 
Capsaicin. NSAIDs and COX-2 inhibitors were used by 
(83.7%), opioids were used by (67.4%), and glucosamine 
was used by (46.5%) for the management of OA (Table 3).
Patients Preferences
The Relative Importance of Attributes
The most important factor in selecting the non-invasive 
pharmaceutical treatment of OA was “risk of heart attacks 
and strokes”, which accounted for 19.5% of the relative 
importance of all attributes. The second most important 
factor was “risk of addiction”; 18.4% of the relative 
importance. Followed by “risk of kidney and liver side- 
effects”; 17.5% of the relative importance. The least 
important factor was “how much mobility improvement 
Table 2 Sawtooth recommended 8 Points to Be Checked Before 
Fielding an ACBC Study
Question Answer
Is this an appropriate study for 
ACBC? Appropriate studies 
typically involve about five or 
more attributes.
Yes. 9 attributes included.
Have you used the Test Design 
capability on the Design tab to 
have the software generate 
dummy (robotic) respondents 
that answer randomly? Have you 
examined the attribute level 
frequency report for these 
dummy test records? Does each 
non-BYO level occur at 
a minimum of 2 times (3 times, 
preferably)?
Yes. Generated and examined 
dummy respondents with 
random responses. 
Each non-BYO question 
appeared 2 times.
Does each respondent evaluate 
no more than about 7 levels per 
attribute?
Yes. Maximum is 4 levels per 
attribute.
If you are studying a large 
number of attributes or levels 
per attribute (such that using 
constructed lists to discard levels 
and attributes from 
consideration within the ACBC 
survey is necessary), is your 
sample size sufficient to stabilize 
the parameters across the full list 
of attributes and levels? Are you 
willing to assume that discarded 
attributes are entirely 
unimportant to the respondent?
N/A. This study does not include 
a large number of attributes and 
levels.
When you take the 
questionnaire, do the 
Unacceptable and Must-Have 
questions properly identify (using 
correct “at least” or “at most” 
phrasing) the levels you have 
consistently selected or 
rejected? (This confirms you set 
the correct worst to best or best 
to worst attribute direction).
Yes. The questionnaire was 
trialed with extreme scenarios 
and has defined the 
Unacceptable & Must-Have 
questions and selected the levels 
appropriately.
Take a practice questionnaires 
yourself, making sure that the 
computed part-worths reflect 
the preferences you expressed in 
the questionnaire
Yes. The questionnaire was 
trialed with specific scenarios 
and produced part-worths that 
match the ranking of the levels in 
these scenarios.
(Continued)
Table 2 (Continued). 
Question Answer
Have you asked colleagues or 
a small convenience sample of 
target respondents to take the 
survey? Have you debriefed them 
regarding their experiences and 
analyzed their data? Were any 
sections/instructions confusing? 
Do the computed part-worth 
utilities reasonably reflect their 
individual preferences? 
Confusing? Do the computed 
part-worth utilities reasonably 
reflect their individual 
preferences?
Yes. This was completed in the 
feasibility studies and was 
repeated by colleagues prior to 
fielding.
Have you fielded the study (a 
“soft launch”) among a few 
target respondents, examining 
the same issues as directly 
above?
Yes. This was completed in the 
feasibility studies and was 
repeated by colleagues prior to 
fielding.
Patient Preference and Adherence 2020:14                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                       
2509




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
would you expect”; only 3.5% of the relative importance 
(Figure 4).
The combined relative importance of the four risk factors 
(kidney and liver, heart attacks and strokes, stomach, and 
addiction side effects) adds up to 70% (17.5% +19.5% 
+14.6% +18.4%) of the total relative importance that impact 
on patients’ decisions when selecting OA medication. The 
combined relative importance of both benefits attributes 
(pain reduction and mobility improvement) accounted only 
for 8.5% (5%+3.5%) of the total relative importance. The 
highest standard deviation between respondents in relation to 
relative importance was 6.3 for the “availability” attribute 
and the lowest was 2.2 for “frequency” attribute.
Utilities of Levels of Attributes
The most preferred medication scenario for participants would 
be prescribed medication that is taken orally, as needed, pro-
vides 75% pain reduction and 75% mobility improvement, and 
has no risk of any of the associated side effects.
The interval utility values in each attribute represent 
how likely the participants would be willing to change 
their mind to trade off a level against another level within 
the same attribute. For example, the utilities for the “no” 
and “low” risk levels in the four risk attributes are in the 
positive value and within close interval values of each 
other in comparison to other levels (“Moderate” and 
“high” risk) that are in the minuses value and within 
large interval values from the most preferred level. This 
means that participants are more likely to trade off the 
“no” and “low” risk levels against each other than they 
would trade them off against levels that are set at the 
other side of the scale. The risk of addiction utilities for 
“No” and “Low” risks are 67.3 and 37.4, and the 
“Moderate” and “High” risks are −6.4 and −98.2, respec-
tively. Therefore, moving from “No” through “Low” and 
“Moderate” to “High” risk, would result in interval losses 
of 29.9, 43.8 and 91.8. This is showing that increasing 
Table 3 Frequency of the Participants’ Age Groups, Gender, 
Years Suffering from OA, Pain Interfere with Normal Life, and 
Using Medications for OA Treatment
Age Group Frequency Male Female
Under 30 1 0 1
30–39 3 0 3
40–49 9 2 7
50–59 8 3 5
60–69 8 2 6
70–79 9 4 5
Over 79 5 2 3
Total 43 13 30
Years suffering from OA Frequency
Less than 5 years 14
5–10 years 12
More than 10 years 16
I do not know 1
Total 43
How much did pain interfere with normal life? Frequency
Not at all 3
A little bit 9
Moderately 16












Codeine or Dihydrocodeine 24
Tramadol 13
(Continued)
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risks of addiction are associated with increasing interval 
disutilities. On the other hand, the risk of liver and 
kidney side effects utilities for “No” and “Low” risks 
are 91.8 and 36.8, and the “Moderate” and “High” risks 
are −63.1 and −65.5, respectively. Therefore, moving 
from “No” through “Low” and “Moderate” to “High” 
risk, would result in interval losses of 55, 99.9 and 2.4. 
This indicates that regarding the risk of liver and kidney 
side effects, it is easier for patients to trade off “High” 
with “Moderate” risk (utility interval 2.4) than trading off 




The results of our study indicate that OA patients are most 
keen to reduce the risk of side effects. For three of the 
attributes of the adverse event (risk of addiction, stomach 
side effects, and heart attacks and strokes), the utility loss 
increases as the risk increases from “no” to “low”, to 
“moderate” to “high”. In the case of the forth adverse 
events attribute (kidney and liver side effects), there is 
only a small difference between moderate and high risk 
of impairment. Across our sample, no reduction in pain or 
improvement would be acceptable if it involved anything 
other than “no” or “low” risk of side effects.
Beyond a relatively strong dislike internet purchases 
(an interval utility of 77 from an over the counter purchase 
compared to a 20.3 interval between prescribed drugs and 
over the counter drugs), the within attribute preferences 
also reveal important other information concerning patient 
preferences for OA: There is little difference between the 
optimal choice of taking medication as needed and once 
per day, but the disutility interval increases when the 
medication is required to be taken more than twice 
per day. This suggests OA patients, on average, most 
prefer medications that are taken most infrequently, that 
are over the counter and taken orally. However; on average 
across the participants, no changes in the frequency of 
medication would compensate for a move from oral to 
cream/gel and no means of taking or frequency would 
compensate a move to internet purchasing, although an 
over the counter oral medication would likely be preferred 
to a prescription cream or gel.
The results of our study are broadly consistent with 
previous research into the preferences for the pharmaceutical 
treatment of OA. Specifically, patients do make trade-offs 
between the benefits treatments might offer and the harms 
that may result from their use and it is the harms that drive 
patient decisions. However, our extensive value set consist-
ing of nine attributes paints a richer picture of the factors that 
affect the medication choices that OA patients make. 
Consistent with previous studies, patient’s medication 
Figure 4 The average (relative) importance and Standard Deviation (SD) for all attributes.
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choices are not driven by the benefits a treatment might 
offer. Rather it is the risk of adverse side effects that most 
influences choices.1,8 Availability, frequency and how the 
medication is taken are more and as least as important as any 
gains in mobility or reductions in pain. Our findings reiterate 
the importance of providing appropriate risk/benefit infor-
mation to patients making decisions about medication for 
their OA.11 They also show that any risk-benefit trade-offs 
should be considered alongside availability and modality.
Although financial attributes were excluded from our 
value set, patients preferred prescription medication over 
medications available without the need to see a doctor. 
This may be related to the age distribution of participants 
and the situation that, in the UK, prescriptions for the over 
60 years of age are free.48 The age profile may also 
explain the dislike of online purchases of medication, as 
older people tend to be generally less perceptive to pro-
ducts offered by online shopping.49 Our results indicates 
that the lower frequency of medication and oral adminis-
tration were preferred, although the strength of preferences 
was smaller than those associated with availability. 
Generally, this is consistence with the patients’ attitude 
toward medication preference in relation to route and 
frequency.50,51
Table 4 The Utilities of All Levels
Attribute Level Utilities Mean Utilities Interval SD
Availability Prescription drug 39.3 26.9
Over-the-counter drug 19.0 20.3 23.3
Internet purchase drug −58.3 77.3 33.5
Frequency As needed 8.2 19.6
Once a day 6.6 1.6 16.9
Twice a day −2.4 9 16.9
3–4 times a day −12.4 10 19.8
Way of taking the medication Oral 17.7 21.4
Cream/Gel −17.7 35.4 21.4
Pain reduction Expect 75% pain reduction 22.1 25.0
Expect 50% pain reduction 1.1 23.2 8.0
Expect 25% pain reduction −23.2 22.1 19.2
Mobility improvement Expect 75% mobility improvement 15.5 16.0
Expect 50% mobility improvement 0.5 15 7.9
Expect 25% mobility improvement −16.0 16.5 14.7
Risk of addiction No risk of addiction 67.3 25.0
Low risk of addiction 37.4 29.9 20.8
Moderate risk of addiction −6.4 43.8 25.2
High risk of addiction −98.2 91.8 34.4
Risk of stomach side effects No risk of stomach ulcer 62.9 28.9
Low risk of stomach ulcer 30.5 32.4 17.3
Moderate risk of stomach ulcer −24.4 54.9 19.7
High risk of stomach ulcer −68.9 44.5 23.4
Risk of kidney and liver side effects No risk of kidney or liver impairment 91.8 27.3
Low risk of kidney or liver impairment 36.8 55 17.0
Moderate risk of kidney or liver impairment −63.1 99.9 18.2
High risk of kidney or liver impairment −65.5 2.4 16.7
Risk of heart attacks and strokes No risk of heart attacks and strokes 93.5 32.5
Low risk of heart attacks and strokes 23.1 70.4 28.0
Moderate risk of heart attacks and strokes −34.9 58 20.6
High risk of heart attacks and strokes −81.6 46.7 22.4
Note: Utilities mean in this table may not add up to ZERO, due to rounding.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                              
Patient Preference and Adherence 2020:14 2512




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Strengths and Limitations
By adopting a novel methodology for collecting patient 
preferences, our study addresses the limitations of pre-
vious studies (and of our previously based pilot study) in 
terms of the numbers of attributes of medication choices 
for OA patients using choice-based experiments. It is the 
most comprehensive study for pharmaceutical treatment 
for OA, including 9 attributes and a total of 31 levels.
Our study recruited 43 respondents; it is potentially 
underpowered and the generalisability to OA population 
might be limited in terms of treatment preferences. 
However, there is no consensus in relation to the sample 
size for conjoint studies. As statistical depends on many 
factors such as the distribution of preferences in the popula-
tion of interest, the number of questions and scenarios 
included in the questionnaire.33 Additionally, ACBC has 
the ability to collect more information from a smaller sam-
ple, potentially reducing required sample sizes and the 
novelty and contribution that the ACBC method proposes 
such as the inclusion of a large number of attributes and 
levels and being a practical tool that can be used to elicit 
patients’ preferences compensate for the study limitation.
In terms of limitations, despite the adaptive nature of 
the process, ACBC interview generally takes longer than 
CBC to complete, the samples needed are smaller than 
standard CBC because more information is captured from 
each individual.52 However, smaller sample sizes may 
compensate for the additional time required to complete 
ACBC surveys and make these methods more useful in 
health service contexts where it might be difficult to 
recruit patient samples large enough to conduct conven-
tional choice-based CA surveys.46
Conclusion
Patients preference for non-invasive pharmaceutical treat-
ment for OA is predominantly driven by patients desire to 
avoid the risk of side effects. In our study, patients were 
not willing to accept any moderate to high risk of side 
effects, even when 50–75% improvement in movement or 
pain reduction was offered. Incorporating patients views 
into decisions about their care has obvious benefits, this 
study introduced ACBC as a practical tool that can be used 
to elicit patients’ preferences for non-invasive pharmaceu-
tical treatment of OA. Further study is required to address 
the validity of the revealed preference in comparison to the 
stated preference and significance of ACBC to practi-
tioners and shared decision-making.
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